Natco Pharma Limited has informed the Exchange about General Updates
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Natco Pharma's Board has given an in-principle approval to evaluate separating (demerging) its Agro business into a standalone entity. The company's core business is pharmaceuticals, and management believes the move will unlock value in the pharma business and allow sharper focus on each business. Natco may retain a small minority stake in the new entity and share services like R&D and patents through Transitional Service Agreements (TSAs) at arm's length pricing. The Board has authorised management to appoint legal and financial advisors, valuers, and merchant bankers to work out the final structure. No demerger ratio, share entitlement, or timeline has been announced yet — the proposal is still at an early evaluation stage.
This is a positive structural step that could unlock hidden value in Natco's pharma business, but it is only an in-principle approval. Investors should wait for concrete details on the demerger ratio, timelines, and NCLT/scheme approvals before drawing firm conclusions on stock impact.